ITPKB (inositol-trisphosphate 3-kinase B) catalyzes the phosphorylation of inositol 1,4,5-trisphosphate (InsP3) to inositol 1,3,4,5-tetrakisphosphate (InsP4), playing crucial roles in calcium homeostasis and cellular signaling 1. The enzyme is essential for B cell survival and development, controlling proapoptotic Bim protein expression in naïve mature B cells and regulating B cell anergy 1. ITPKB demonstrates significant clinical relevance in cancer biology, where it functions as a key regulator of reactive oxygen species (ROS) homeostasis. In glioblastoma, ITPKB upregulation correlates with temozolomide resistance through ROS modulation, with its stability maintained by decreased Trim25-mediated ubiquitination 2. Similarly, in ovarian cancer, CAMK2G-mediated phosphorylation of ITPKB at serine 174 drives cisplatin resistance by maintaining redox homeostasis 3. The protein serves as a prognostic biomarker and therapeutic target across multiple cancers, including Hodgkin lymphoma where it defines oncogene-driven subtypes 4 and colorectal cancer where it functions downstream of miR-410 regulation 5. Additionally, ITPKB variants show protective associations with Parkinson's disease risk in Taiwanese populations 6 and represent potential diagnostic markers for Alzheimer's disease 7.